Our People Anna Mudge

Anna works closely with her life sciences clients through all stages of the patenting process: from original drafting and global IP strategy to EPO oppositions and freedom-to-operate projects.  She has an impressive track record in offensive EPO oppositions, through which she helps her clients to avoid or clear competitor patents.  She is highly experienced at managing large-scale freedom-to-operate projects to support her clients’ pre-clinical and clinical programmes.

Anna leads our Advanced Therapeutics team which focuses on cell and gene technologies.

Areas of Expertise

• Cell therapy
• Gene therapy
• Nucleic acid and antisense technology
• Viral delivery technology
• Immunotherapy
• Antibody technology
  

Clients

Anna works with a wide range of organisations including established biotech companies, biotech start-ups, spin-outs and universities. She works predominantly with clients based in the UK, the US and Singapore.

Background

Anna has a first class BSc in Molecular Biology and Biochemistry and a PhD, both from Durham University. Her doctorate specialised in the molecular mechanisms of plant root growth. She joined Mewburn Ellis LLP in 2015, qualifying as a Chartered Patent Attorney and a European Patent Attorney in 2019.

Opposition Highlights

Anna has worked on over 12 oppositions. Here are some of the top cases she has worked on:

EP3031920 - Forced the proprietor to self-revoke the patent during opposition proceedings, helping to clear the way for a mid-sized biotech client.  

EP3636778 - Successful revocation by the Opposition Division, which was very important to our client and their development of similar therapies. 

Recommendations

Anna is named as a ‘Rising Star’ in the Managing Intellectual Property’s IP Stars 2022 and 2023.